Aim: This study calculated the effects on creatine phosphokinase MB (CK-MB) levels, after treatment with either of 2 drugs: the erythropoietin (Epo) and the Antioxidant lazaroid (L) drug U-74389G. The calculation was based on the results of 2 preliminary studies, each one of which estimated the certain influence, after the respective drug usage in an induced ischemia reperfusion (IR) animal experiment. Materials and Methods: The 2 main experimental endpoints at which the serum CK-MB levels (CK-MBl) were evaluated was the 60th reperfusion min (for the groups A, C and E) and the 120th reperfusion min (for the groups B, D and F). Specially, the groups A and B were processed without drugs, groups C and D after Epo administration; whereas groups E and F after the L administration. Results: The first preliminary study of Epo presented a non-significant CK-MBl restoring effect by 2.85%+3.80% (p-value=0.4430). The second preliminary study of U-74389G presented a significant CK-MBl restoring effect by 11.40%+3.08% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that Epo is 3.989339-fold [3.980903 - 3.997794] more recessing than Epo (p-value=0.0000) on CK-MBl. Conclusions: The anti-oxidant capacities of U-74389G ascribe 3.989339-fold less recessing effects than Epo (p-value=0.0000) on CK-MBl.